The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Eteplirsen in the treatment of Duchenne muscular dystrophy
Open accessAbstract
Duchenne muscular dystrophy is a fatal neuromuscular disorder affecting around one in 3,500–5,000 male births that is characterized by progressive muscular deterioration. It is inherited in an X-linked recessive fashion and is caused by loss-of-function mutations in the DMD gene coding for dystrophin, a cytoskeletal protein that stabilizes the plasma membrane of muscle fibers. In September 2016, the US Food and Drug Administration granted accelerated approval for eteplirsen (or Exondys 51), a drug that acts to promote dystrophin production by restoring the translational reading frame of DMD through specific skipping of exon 51 in defective gene variants. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available information on eteplirsen to date, focusing on pharmacological, efficacy, safety, and tolerability data from preclinical and clinical trials. Issues faced by eteplirsen, particularly those relating to its efficacy, will be identified. Finally, the place of eteplirsen and exon skipping as a general therapeutic strategy in Duchenne muscular dystrophy treatment will be discussed. Keywords: Duchenne muscular dystrophy, eteplirsen, Exondys 51, exon-skipping therapy, phosphorodiamidate morpholino oligomers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693 · cited 1×
“Duchenne muscular dystrophy (DMD): introduction and management issues in treatment DMD is a fatal X-linked recessive neuromuscular disorder characterized by progressive muscle weakening and wasting.(1) It affects around one in 3,500–5,000 males born worldwide.”
BackgroundKoenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein
Koenig, M., Monaco, A. P., & Kunkel, L. M. (1988) · Cell · doi:10.1016/0092-8674(88)90383-2 · Cited by 1,538
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448
A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin
Ervasti, J., & Campbell, K. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.4.809 · Cited by 1,388
Membrane organization of the dystrophin-glycoprotein complex
Ervasti, J. M., & Campbell, K. P. (1991) · Cell · doi:10.1016/0092-8674(91)90035-w · Cited by 1,329
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D., Yu, R., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 845
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
Evidence-based path to newborn screening for Duchenne muscular dystrophy
Mendell, J. R., Shilling, C., Leslie, N. D., Flanigan, K. M., al‐Dahhak, R., Gastier‐Foster, J., Kneile, K., Dunn, D. M., Duval, B., Aoyagi, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.23528 · Cited by 813
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H., Lamont, L., Roy, A. J., Chamova, T., et al. (2015) · Human Mutation · doi:10.1002/humu.22758 · Cited by 729
Kinali, M., Arechavala-Gomeza, V., Feng, L., Cirak, S., Hunt, D., Adkin, C., Guglieri, M., Ashton, E., Abbs, S., Nihoyannopoulos, P., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70211-x · Cited by 653
Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Mendell, J. R., Goemans, N., Lowes, L. P., Alfano, L. N., Berry, K., Shao, J., Kaye, E. M., Mercuri, E., & for the Eteplirsen Study Group and Telethon Foundation DMD Italian Network (2016) · Annals of Neurology · doi:10.1002/ana.24555 · Cited by 518
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.
Dominski, Z., & Kole, R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8673 · Cited by 426
Biggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.01.010 · Cited by 371
Mamchaoui, K., Trollet, C., Bigot, A., Negroni, E., Chaouch, S., Wolff, A., Kandalla, P. K., Marie, S., Di Santo, J., St Guily, J. L., et al. (2011) · Skeletal Muscle · doi:10.1186/2044-5040-1-34 · Cited by 340
Dystrophin, its interactions with other proteins, and implications for muscular dystrophy
Ervasti, J. M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.05.010 · Cited by 324
Takeshima, Y., Yagi, M., Okizuka, Y., Awano, H., Zhang, Z., Yamauchi, Y., Nishio, H., & Matsuo, M. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.49 · Cited by 248
Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy
Mayhew, A., Mazzone, E. S., Eagle, M., Duong, T., Ash, M., Decostre, V., Vandenhauwe, M., Klingels, K., Florence, J., Main, M., et al. (2013) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12213 · Cited by 229
Yin, H., Moulton, H. M., Seow, Y., Boyd, C., Boutilier, J., Iverson, P., & Wood, M. J. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn293 · Cited by 224
Advances in Duchenne muscular dystrophy gene therapy
van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1180 · Cited by 221
Exon skipping therapy for Duchenne muscular dystrophy
Kole, R., & Krieg, A. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.008 · Cited by 192
White, S., Kalf, M., Liu, Q., Villerius, M., Engelsma, D., Kriek, M., Vollebregt, E., Bakker, B., van Ommen, G.-J. B., Breuning, M. H., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/341942 · Cited by 180
Bushby, K., & Connor, E. (2011) · Clinical Investigation · doi:10.4155/cli.11.113 · Cited by 159
Evidence and anecdotes: an analysis of human gene patenting controversies
Caulfield, T., Cook-Deegan, R. M., Kieff, F. S., & Walsh, J. P. (2006) · Nature Biotechnology · doi:10.1038/nbt0906-1091 · Cited by 153
Arechavala‐Gomeza, V., Graham, I. R., Popplewell, L. J., Adams, A. M., Aartsma-Rus, A. M., Kinali, M., Morgan, J. E., van Deutekom, J. C., Wilton, S. D., Dickson, G., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.061 · Cited by 152
Aoki, Y., Nakamura, A., Yokota, T., SAITO, T. K., Okazawa, H., Nagata, T., & Takeda, S. (2010) · Molecular Therapy · doi:10.1038/mt.2010.186 · Cited by 140
Self-citationCurrent and emerging treatment strategies for Duchenne muscular dystrophy
Mah, J. K. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s93873 · Cited by 140
Forbes, S. C., Willcocks, R. J., Triplett, W. T., Rooney, W. D., Lott, D. J., Wang, D.-J., Pollaro, J., Senesac, C., Daniels, M. J., Finkel, R. S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106435 · Cited by 115
Patents in Genomics and Human Genetics
Cook-Deegan, R. M., & Heaney, C. D. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141811 · Cited by 111
Approving a Problematic Muscular Dystrophy Drug
Kesselheim, A. S., & Avorn, J. (2016) · JAMA · doi:10.1001/jama.2016.16437 · Cited by 103
Splicing therapy for neuromuscular disease
Douglas, A. G. L., & Wood, M. J. A. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2013.04.005 · Cited by 100
Chemical treatment enhances skipping of a mutated exon in the dystrophin gene
Nishida, A., Kataoka, N., Takeshima, Y., Yagi, M., Awano, H., Ota, M., Itoh, K., Hagiwara, M., & Matsuo, M. (2011) · Nature Communications · doi:10.1038/ncomms1306 · Cited by 98
Straub, V. W., Balabanov, P. P., Bushby, K. M. D., Ensini, M., Goemans, N., Luca, A. D., Pereda, A., Hemmings, R., Campion, G., Kaye, E. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30035-7 · Cited by 95
Functional Rescue of Dystrophin-deficient mdx Mice by a Chimeric Peptide-PMO
Yin, H., Moulton, H. M., Betts, C., Merritt, T. M., Seow, Y., Ashraf, S., Wang, Q., Boutilier, J. K., & Wood, M. J. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.151 · Cited by 81
Antisense Therapy in Neurology
Lee, J. K., & Yokota, T. (2013) · Journal of Personalized Medicine · doi:10.3390/jpm3030144 · Cited by 81
Self-citationRicotti, V., Evans, M. R. B., Sinclair, C. D. J., Butler, J. W., Ridout, D. A., Hogrel, J., Emira, A., Morrow, J. M., Reilly, M. M., Hanna, M. G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162542 · Cited by 68
Optimizing exon skipping therapies for DMD.
Yokota, T., Duddy, W. J., & Partridge, T. A. (2007) · Europe PMC (PubMed Central) · Cited by 67
Self-citationEchigoya, Y., Mouly, V., García, L., Yokota, T., & Duddy, W. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120058 · Cited by 67
Self-citationMutation rates in the dystrophin gene: A hotspot of mutation at a CpG dinucleotide
Buzin, C. H., Feng, J., Jin, Y., Scaringe, W. A., Liu, Q., den Dunnen, J. T., Mendell, J. R., & Sommer, S. S. (2005) · Human Mutation · doi:10.1002/humu.20132 · Cited by 63
Skipping Multiple Exons of Dystrophin Transcripts Using Cocktail Antisense Oligonucleotides
Echigoya, Y., & Yokota, T. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0451 · Cited by 57
Self-citationNichols, B. M., Takeda, S., & Yokota, T. (2015) · Brain Sciences · doi:10.3390/brainsci5030275 · Cited by 51
Self-citationHexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice
Han, G., Gu, B., Cao, L., Gao, X., Wang, Q., Seow, Y., Zhang, N., Wood, M. J. A., & Yin, H. (2016) · Nature Communications · doi:10.1038/ncomms10981 · Cited by 48
Yokota, T., Duddy, W. J., Echigoya, Y., & Kolski, H. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.693469 · Cited by 44
Self-citationSafety Pharmacology and Genotoxicity Evaluation of AVI-4658
Sazani, P., Weller, D. L., & Shrewsbury, S. B. (2010) · International Journal of Toxicology · doi:10.1177/1091581809359206 · Cited by 41
FDA grants accelerated approval to first drug for Duchenne muscular dystrophy
(2016) · Case Medical Research · doi:10.31525/cmr-29dc5f3 · Cited by 38
Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan
Goto, M., Komaki, H., Takeshita, E., et al. (2016) · Brain and Development · doi:10.1016/j.braindev.2016.04.001 · Cited by 25
Cited by
The current landscape of nucleic acid therapeutics
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., & van der Meel, R. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00898-0 · Cited by 1,371
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., & Bahal, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9062004 · Cited by 545
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Metadata
- Authors
- Lim, K. R., Maruyama, R., & Yokota, T.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- Volume11
- Pages
- 533-545
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2593956993
- Cited by
- 495
- References
- 53
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.